Hemagglutinating virus of Japan protein is efficient for induction of CD4+ T-cell response by a hepatitis B core particle-based HIV vaccine

Clinical Immunology

Volumn 112, Issue 1, 2004, Pages 92-105

  Takeda, Satoshi ^a   Shiosaki, Kouichi ^b   Kaneda, Yasufumi ^c   Nakasatomi, Tetsuya ^a   Yoshizaki, Hitomi ^a   Someya, Kenji ^a   Konno, Yusuke ^c   Eda, Yasuyuki ^b   Kino, Youichirou ^b   Yamamoto, Naoki ^a   Honda, Mitsuo ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b Chemo Sero Therapeutic Research Institute   (Japan)

^c OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

chimeric HIV V3 HBc particle; HBc; hemagglutinating virus of Japan; hepatitis B core protein; HIV HBc; HIV hepatitis B core chimeric protein; HIV specific immunity; HVJ; HVJ protein incorporated liposome; Synergy of IL 18 and 12 to secrete IFN

Indexed keywords

ANTISERUM; GAMMA INTERFERON; HEMAGGLUTINATING VIRUS OF JAPAN PROTEIN; HEPATITIS B CORE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 12; INTERLEUKIN 18; LIPOSOME; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EMBRYO; FEMALE; GENE INDUCTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; INTERFERON PRODUCTION; MOUSE; NONHUMAN; PARAINFLUENZA VIRUS 1; PRIORITY JOURNAL; SPLEEN CELL; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VACCINATION; VIRUS PARTICLE;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GUINEA PIGS; HEPATITIS B CORE ANTIGENS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; IMMUNIZATION; INTERFERON TYPE II; INTERLEUKINS; LIPOSOMES; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; RECOMBINANT FUSION PROTEINS; SENDAI VIRUS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 2942695979     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clim.2004.04.001     Document Type: Article

References (64)

1. Hansen J., Schulze T., Moelling K. RNase H activity associated with bacterially expressed reverse transcriptase of human T-cell lymphotropic virus III/lymphadenopathy-associated virus. J. Biol. Chem. 262:1987;12393-12396
2. Wu X., Liu H., Xiao H., Kim J., Seshaiah P., Natsoulis G., Boeke J.D., Hahn B.H., Kappes J.C. Targeting foreign proteins to human immunodeficiency virus particles via fusion Vpr and Vpx. J. Virol. 69:1995;3389-3398
3. Charbit A., Martineau P., Ronco J., Leclerc C., Lo-Man R., Michel V., O'Callaghan D., Hofnung M. Expression and immunogenicity of the V3 loop from the envelope of human immunodeficiency virus type 1 in an attenuated aroA strain of Salmonella typhimurium upon genetic coupling to two Escherichia coli carrier proteins. Vaccine. 11:1993;1221-1228
4. Stover C.K., de la Cruz V.F., Bansal G.P., Young J.F., Lee M.H., Hatfull G.F., Snappe S.B., Barletta R.G., Jacobs W.R. Jr., Bloom B.R. New use of BCG for recombinant vaccines. Nature. 351:1991;456-460
5. Natuk R.J., Chanda P.K., Lubeck M.D., Davis A.R., Wilhelm J., Hjorth R., Wade M.S., Bhat B.M., Mizutani S., Lee S., Eichberg J., Gallo R.C., Hung P.P., Robert-Guroff M. Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model. Proc. Natl. Acad. Sci. U. S. A. 89:1992;7777-7781
6. Hanke T., Samuel R.V., Blanchard T.J., Neumann V.C., Allen T.M., Boyson J.E., Sharpe S.A., Cook N., Smith G.L., Watkins D.I., Cranage M.P., McMichael A.J. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. 73:1999;7524-7532
7. Barnett S.W., Rajasekar S., Legg H., Doe B., Fuller D.H., Haynes J.R., Walker C.M., Steimer K.S. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine. 15:1997;869-873
8. Berzofsky J.A., Ahlers J.D., Derby M.A., Pendleton C.D., Arichi T., Belyakov I.M. Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections. Immunol. Rev. 170:1999;151-172
9. Belyakov I.M., Wyatt L.S., Ahlers J.D., Earl P., Pendleton C.D., Kelsall B.L., Strober W., Moss B., Berzofsky J.A. Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein. J. Virol. 72:1998;8264-8272
10. Ho D. Long-term non-progressor. 10th International Conference on AIDS (Yokohama). vol. I:1994;50
11. + T cell responses associated with control of viremia. Science. 278:1997;1447-1450
12. Ahlers J.D., Pendleton C.D., Dunlop N., Minassian A., Nara P.L., Berzofsky J.A. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations. J. Immunol. 150:1993;5647-5665
13. Fehr T., Skrastina D., Pumpens P., Zinkernagel R.M. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. Proc. Natl. Acad. Sci. U. S. A. 95:1998;9477-9481
14. Schodel F., Milich D.R., Will H. Hepatitis B virus nucleocapsid/pre-S2 fusion proteins expressed in attenuated Salmonella for oral vaccination. J. Immunol. 145:1990;4317-4321
15. Shiosaki K., Tanaka K., Nishimura S., Mizokami H., Matsubara K. Production of hepatitis B virion-like particles in yeast. Gene. 106:1991;143-149
16. Schodel F., Moriarty A.M., Peterson D.L., Zheng J., Hughes J.L., Will H., Leturcq D.J., McGee J.S., Milich D.R. The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity. J. Virol. 66:1992;106-114
17. + cytotoxic T-lymphocyte responses after genetic immunization with retrovirus vectors expressing different forms of the hepatitis B virus core and e antigens. J. Virol. 71:1997;3365-3374
18. Miyanohara A., Imamura T., Araki M., Sugawara K., Ohmoto N., Matsubara K. Expression of hepatitis B virus core antigen gene in Saccharomyces cerevisiae: synthesis of two polypeptides translated from different initiation codons. J. Virol. 59:1986;176-180
19. Milich D.R., McLachalan A., Thornton G.B., Hughes J.L. Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site. Nature. 329:1987;547-549
20. Clarke B.E., Newton S.E., Carroll A.R., Francis M.J., Appleyard G., Syred A.D., Highfield P.E., Rowlands D.J., Brown F. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature. 330:1987;381-384
21. Moriarty A.M., McGee J.S., Winslow B.J., Enman D.W., Leturcq D.J., Thornton G.B., Hughes J.L., Milich D.R. Expression of HIV gag and env B-cell epitopes on the surface of HBV core particles and analysis of the immune responses generated to those epitopes. Brown F., Chanock R.M., Ginsberg H.S., Lerner R.A. Vaccines. vol. 90:1990;225 Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
22. Stahl S.J., Murray K. Immunogenicity of peptide fusions to hepatitis B virus core antigen. Proc. Natl. Acad. Sci. U. S. A. 86:1989;6283-6287
23. Borisova G.P., Berzins I., Pushko P.M., Pumpen P., Gren E.J., Tsibinogin V.V., Loseva V., Ose V., Ulrich R., Siakkou H., Rosenthal H.A. Recombinant core particles of hepatitis B virus exposing foreign antigenic determinants on their surface. FEBS Lett. 259:1989;121-124
24. Schodel F., Weimer T., Will H., Milich D. Recombinant HBV core particles carrying immunodominant B-cell epitopes of the HBV pre-S2 region. Brown F., Chanock R.M., Ginsberg H.S., Lerner R.A. Vaccines. vol. 90:1990;193 Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
25. Schodel F., Milich D.R., Will H. Hybrid hepatitis B virus core/PreS particles expressed in live attenuated Salmonellae for oral immunization. Brown F., Chanock R.M., Ginsberg H.S., Lerner R.A. Vaccines. vol. 91:1991;319 Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
26. Clarke B.E., Carroll A.R., Brown A.L., Jon J., Parry N.R., Rud E.W., Francis M.J., Rowland D.J. Expression and immunologic analysis of hepatitis-B core fusion particles carrying internal heterologous sequences. Brown F., Chanock R.M., Ginsberg H.S., Lerner R.A. Vaccines. vol. 91:1991;313 Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
27. Boudet F., Girard M., Theze J., Zouali M. Antibodies of HIV-1 positive subjects and experimentally immunized primates and rodents bind to sequence divergent regions of the third variable domain (V3) of gp120. Int. Immunol. 4:1992;283-294
28. Takahashi H., Cohen J., Hosmalin A., Cease K.B., Houghten R., Cornette J.L., DeLisi C., Moss B., Germain R.N., Berzofsky J.A. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 85:1988;3105-3109
29. Moore J.P., Binley J. HIV. Envelope's letters boxed into shape. Nature. 393:1998;630-631
30. Rizzuto C.D., Wyatt R., Hernandez-Ramos N., Sun Y., Kwong P.D., Hendrickson W.A., Sodroski J. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science. 280:1998;1949-1953
31. Wyatt R., Kwong P.D., Desjardins E., Sweet R.W., Robinson J., Hendrickson W.A., Sodroski J.G. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 393:1998;705-711
32. Carotenuto P., Looij D., Keldermans L., de Wolf F., Goudsmit J. Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. AIDS. 12:1998;1591-1600
33. Zhang Y.J., Fracasso C., Fiore J.R., Bjorndal A., Angarano G., Gringeri A., Fenyo E.M. Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. J. Infect. Dis. 176:1997;1180-1187
34. Imamura T., Araki M., Miyanohara A., Nakao J., Yonemura H., Ohtomo N., Matsubara K. Expression of hepatitis B virus middle and large surface antigen genes in Saccharomyces cerevisiae. J. Virol. 61:1987;3543-3549
35. Matsushita S., Robert-Guroff M., Rusche J., Koito A., Hattori T., Hoshino H., Javaherian K., Takatsuki K., Putney S. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J. Virol. 62:1988;2107-2114
36. Okamoto Y., Eda Y., Ogura A., Shibata S., Amagai T., Katsura Y., Asano T., Kimachi K., Makizumi K., Honda M. In SCID-hu mice, passive transfer of a humanized antibody prevents infection and atrophic change of medulla in human thymic implant due to intravenous inoculation of primary HIV-1 isolate. J. Virol. 160:1988;69-76
37. Saeki Y., Kaneda Y. Protein modified liposomes (HVJ-liposomes) for the delivery of genes, oligonucleotides and protein. Celis J.E. second ed. Cell Biology: A Laboratory Handbook. vol. 4:1998;127 Academic Press Inc. San Diego
38. Kaneda Y. Virus (sendai virus envelopes) mediated gene transfer. Celis J.E. first ed. Cell Biology: A Laboratory Handbook. vol. 3:1994;50 Academic Press Inc. San Diego
39. Saeki Y., Matsumoto N., Nakano Y., Mori M., Awai K., Kaneda Y. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus); reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum. Gene Ther. 8:1997;2133-2141
40. Hiroi T., Goto H., Someya K., Yanagita M., Honda M., Yamanaka N., Kiyono H. HIV mucosal vaccine: nasal immunization with rBCG-V3J1 induces a long term V3J1 peptide-specific neutralizing immunity in Th1- and Th2-deficient conditions. J. Immunol. 167:2001;5862-5867
41. Takahashi H., Merli S., Putney S.D., Houghten R., Moss B., Germain R.N., Berzofsky J.A. A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp160. Science. 246:1989;118-121
42. Takahashi H., Nakagawa Y., Leggatt G.R., Ishida Y., Saito T., Yokomuro K., Berzofsky J.A. Inactivation of human immunodeficiency virus (HIV)-1 envelope-specific CD8+ cytotoxic T lymphocytes by free antigenic peptide: a self-veto mechanism? J. Exp. Med. 183:1996;879-889
43. Honda M., Matsuo K., Nakasone T., Okamoto Y., Yoshizaki H., Kitamura K., Sugiura W., Watanabe K., Fukushima Y., Haga S., Katsura Y., Tasaka H., Komuro K., Yamada T., Asano T., Yamazaki A., Yamazaki S. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guerin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. Proc. Natl. Acad. Sci. U. S. A. 92:1995;10693-10697
44. Honda M., Chan C., Shevach E.M. Characterization and partial purification of a specific interleukin 2 inhibitor. J. Immunol. 135:1985;1834-1839
45. Honda M., Yamamoto S., Cheng M., Yasukawa K., Suzuki H., Saito T., Osugi Y., Tokunaga T., Kishimoto T. Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J. Immunol. 148:1992;2175-2180
46. Gorny M.K., Moore J.P., Conley A.J., Karwowska S., Sodroski J., Williams C., Burda S., Boots L.J., Zolla-Pazner S. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J. Virol. 68:1994;8312-8320
47. Sakaue G., Hiroi T., Nakagawa Y., Someya K., Iwatani K., Sawa Y., Takahashi H., Honda M., Kunisawa J., Kiyono H. HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses. J. Immunol. 170:2003;495-502
48. Kaneda Y., Iwai K., Uchida T. Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Science. 243:1989;375-378
49. Kitajima I., Hanyu N., Soejima Y., Hirano R., Arahira S., Yamaoka S., Yamada R., Maruyama I., Kaneda Y. Efficient transfer of synthetic ribozymes into cells using hemagglutinating virus of Japan (HVJ)-cationic liposomes. Application for ribozymes that target human t-cell leukemia virus type I tax/rex mRNA. J. Biol. Chem. 272:1997;27099-27106
50. Ito Y., Nishiyama Y., Shimokata K., Nagata I., Takeyama H., Kunii A. The mechanism of interferon induction in mouse spleen cells stimulated with HVJ. Virology. 88:1978;128-137
51. Fukuda S., Ando S., Sanou O., Taniai M., Fujii M., Masaki N., Nakamura K., Ando O., Torigoe K., Sugimoto T., Kurimoto M. Simultaneous production of natural human tumor necrosi factor-alpha, -beta and interferon-alpha from BALL-1 cells stimulate by HVJ. Lymphokine Res. Summer. 7:1988;175-185
52. Pirhonen J., Sareneva T., Kurimoto M., Julkunen I., Matikainen S. Virus infection activates IL-1 beta and IL-18 production in human macrophages by a caspase-1-dependent pathway. J. Immunol. 162:1999;7322-7329
53. Yoshimoto T., Tsutsui H., Tominaga K., Hoshino K., Okamura H., Akira S., Paul W.E., Nakanishi K. IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc. Natl. Acad. Sci. U. S. A. 96:1999;13962-13966
54. Hofstra C.L., Van Ark I., Hofman G., Kool M., Nijkamp F.P., Van Oosterhout A.J. Prevention of Th2-like cell responses by coadministration of IL-12 and IL-18 is associated with inhibition of antigen-induced airway hyperresponsiveness, eosinophilia, and serum IgE levels. J. Immunol. 161:1998;5054-5060
55. Xu D., Chan W.L., Leung B.P., Hunter D., Schulz K., Carter R.W., McInnes I.B., Robinson J.H., Liew F.Y. Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells. J. Exp. Med. 188:1998;1485-1492
56. Almeida J.D., Edwards D.C., Brand C.M., Heath T.D. Formation of virosomes from influenza subunits and liposomes. Lancet. 2:1975;899-901
57. + CTL in vivo with peptide vaccine constructs. J. Immunol. 152:1994;549-556
58. Lasarte J.J., Sarobe P., Gullon A., Prieto J., Borras-Cuesta F. Induction of cytotoxic T lymphocytes in mice against the principal neutralizing domain of HIV-1 by immunization with an engineered T-cytotoxic-T-helper synthetic peptide construct. Cell Immunol. 141:1992;211-218
59. Widemann C., Romero P., Maryanski J.L., Corradin G., Valmori D. T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides. J. Immunol. Methods. 155:1992;95-99
60. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D., Riddell S.R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1995;1038-1044
61. Martinon F., Michelet C., Peguillet I., Taoufik Y., Lefebvre P., Goujard C., Guillet J.G., Delfraissy J.F., Lantz O. Persistent alterations in T-cell repertoire, cytokine and chemokine receptor gene expression after 1 year of highly active antiretroviral therapy. AIDS. 13:1999;185-194
62. Kent S.J., Zhao A., Best S.J., Chandler J.D., Boyle D.B., Ramshaw I.A. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol. 72:1998;10180-10188
63. Ostrowski M.A., Chun T.W., Justement S.J., Motola I., Spinelli M.A., Adelsberger J., Ehler L.A., Mizell S.B., Hallahan C.W., Fauci A.S. Both memory and CD45RA+/CD62L+ naive CD4(+) T cells are infected in human immunodeficiency virus type 1-infected individuals. J. Virol. 73:1999;6430-6435
64. Zajac A.J., Blattman J.N., Murali-Krishna K., Sourdive D.J.D., Suresh M., Altman J.D., Ahmed R. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188:1998;2205-2213